NCT05939362 · RECRUITING
New Imaging Biomarkers Predictive of MA Progression
This trial is testing whether ultra-high-field 7 Tesla MRI, combined with a technique called magnetic resonance spectroscopy, can detect early metabolic changes in the brains of people with early-stage Alzheimer's disease. Researchers hope these scans can predict how the disease will progress over time. This is a Phase N/A observational imaging study, meaning it is not testing a drug or treatment — just gathering detailed brain measurements.
Eligibility criteria
Inclusion Criteria: * French-speaking patients aged 60 to 90 years, * Patient in the context of Alzheimer's disease * for which imaging after MRI is prescribed as part of the usual diagnostic process, *Alzheimer's disease is diagnosed by the doctor of the memory consultation and is defined by :Evidence of a storage disorder in verbal episodic memory at LR/RI defined by a sum of LR \< 17/48 and sum of RT \< 40/48 +/- Impairment of executive functions possible (BREF, TMT grefex, verbal fluencies) +/- Impairment of instrumental functions possible (Grémots noun naming, Rey's figure, Mahieux's Battery). * MMSE score ≥18, * Written informed consent after the patient has been informed, * Progressive decline for at least 6 months. Exclusion Criteria: --Partially or completely illiterate patient unable to read and write, * Patient with an absolute contraindication to 7T MRI * Severe psychiatric pathology not balanced, * Non-degenerative neurological disease (stroke, multiple sclerosis ...), * Patient with tumor or inflammatory pathology, or vascular leukopathy visualized in MRI (Fazekas score > 3)
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2024-12-10